Literature DB >> 2805289

Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy.

M T Olivari1, D C Homans, R F Wilson, S H Kubo, W S Ring.   

Abstract

Although triple-drug immunosuppression with cyclosporine, prednisone, and azathioprine has reduced the incidence of acute graft rejection after cardiac transplant, its effect on the development of coronary artery disease is unknown. We have followed up 74 cardiac transplant recipients with yearly coronary angiograms. The probability of acute rejection was 10.8% at 1 year. The incidence of coronary artery disease was 8% at 1 year (six of 74 patients) and 24% at 2 years (11 of 30 patients). In patients who developed posttransplant coronary artery disease, there was a slightly higher, but not statistically significant, incidence of acute graft rejection and pretransplant idiopathic cardiomyopathy. No correlation was found between the incidence of coronary artery disease and recipient age, human leukocyte antigen (HLA) type, hypertension, diabetes, cholesterol level, triglyceride levels, weight gain after transplant, and smoking. These data indicate that triple-drug immunosuppression, despite having produced a significant reduction in the episodes of acute graft rejection, has not decreased the incidence of posttransplant coronary artery disease. Common risk factors for coronary disease and HLA mismatch are probably not important in the pathogenesis of coronary atherosclerosis after cardiac transplantation, whereas the risk for coronary artery disease may be increased by acute graft rejection and pretransplant idiopathic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805289

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  CD8+ T lymphocytes mediate destruction of the vascular media in a model of chronic rejection.

Authors:  J F Légaré; T Issekutz; T D Lee; G Hirsch
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

Review 2.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Transplant Coronary Vasculopathy.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-02

Review 4.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

Review 5.  [Diabetes and heart transplantation].

Authors:  M Loebe; K Ramasubbu; D J Hamilton
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

Review 6.  Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation.

Authors:  Amandeep Dhaliwal; Vinay Thohan
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

7.  Alterations in the fibrinolytic cascade post-transplant: evidence of a bimodal expression pattern.

Authors:  Raymond L Benza; Matthew A Cavender; Joseph Barchue; Jose A Tallaj; Robert C Bourge; James K Kirklin; Christopher S Coffey
Journal:  J Heart Lung Transplant       Date:  2007-05       Impact factor: 10.247

Review 8.  Surgical approaches to dilated cardiomyopathy.

Authors:  I A Smolens; S F Bolling
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

9.  The incidence of aspirin resistance in heart transplantation recipients.

Authors:  Tomasz Urbanowicz; Anna Komosa; Michał Michalak; Tatiana Mularek; Veronica Cassadei; Stefan Grajek; Marek Jemielity
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-06-30

10.  Network reconstruction and validation of the Snf1/AMPK pathway in baker's yeast based on a comprehensive literature review.

Authors:  Timo Lubitz; Niek Welkenhuysen; Sviatlana Shashkova; Loubna Bendrioua; Stefan Hohmann; Edda Klipp; Marcus Krantz
Journal:  NPJ Syst Biol Appl       Date:  2015-10-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.